Bupropion hydrochloride in attention deficit disorder with hyperactivity

C. Keith Conners, Charles D. Casat, C. Thomas Gualtieri, Elizabeth Weller, Mark Reader, Allan Reiss, Ronald A. Weller, Moise Khayrallah, John Ascher

Research output: Contribution to journalArticle

Abstract

Objective: This is a multisite, double-blind, placebo-controlled trial to determine the safety and efficacy of bupropion in the treatment of children with attention deficit disorder with hyperactivity (ADDH). Method: In a four-center, double-blind comparison of bupropion (n = 72) and placebo (n = 37), children aged 6 to 12 years meeting DSM-III criteria for ADDH were randomized to receive bupropion 3 to 6 mg/kg per day or placebo, administered twice daily, at 7 A.M. and 7 P.M. Measures of efficacy included the Conners Parent and Teacher Questionnaires (93-item, 39-item, and 10-item), Clinical Global Impressions Scales of Severity and Improvement, the Sternberg Short- Term Memory Task, and the Continuous Performance Test Screen and posttreatment physical examinations, electrocardiograms, electroencephalograms, and clinical laboratory evaluations were performed. Height, weight, and vital signs were measured and adverse experiences were assessed weekly. Results: A significant treatment effect, apparent as early as day 3, was present for both conduct problems and hyperactivity on the Conners 10-item and 30-item teacher's checklist, and at day 28 for conduct problems and restless-impulsive behavior on the 93-item parent questionnaire. Findings were of smaller magnitude for parent ratings than teacher ratings. Significant treatment effects were present on both the Continuous Performance Test and memory retrieval test. Effect sizes of bupropion/placebo differences for teacher and parent ratings in this study were somewhat smaller than for standard stimulant drugs used to treat ADDH. Bupropion appeared to be well tolerated in most children. Dermatological reactions were twice as frequent in the drug group as the placebo group, with four reactions involving rash and urticaria that were serious enough to require discontinuation of medication. Conclusions: Bupropion may be a useful addition to available treatments for ADDH. Comparative trials with such standard drugs as methylphenidate are warranted to determine the relative clinical merits of bupropion.

Original languageEnglish (US)
Pages (from-to)1314-1321
Number of pages8
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume35
Issue number10
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Bupropion
Attention Deficit Disorder with Hyperactivity
Placebos
Pharmaceutical Preparations
Methylphenidate
Impulsive Behavior
Vital Signs
Urticaria
Task Performance and Analysis
Therapeutics
Exanthema
Checklist
Short-Term Memory
Diagnostic and Statistical Manual of Mental Disorders
Physical Examination
Electroencephalography
Electrocardiography
Safety
Weights and Measures

Keywords

  • attention deficit disorder with hyperactivity
  • attention- deficit hyperactivity disorder
  • bupropion

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

Bupropion hydrochloride in attention deficit disorder with hyperactivity. / Conners, C. Keith; Casat, Charles D.; Gualtieri, C. Thomas; Weller, Elizabeth; Reader, Mark; Reiss, Allan; Weller, Ronald A.; Khayrallah, Moise; Ascher, John.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 35, No. 10, 01.01.1996, p. 1314-1321.

Research output: Contribution to journalArticle

Conners, CK, Casat, CD, Gualtieri, CT, Weller, E, Reader, M, Reiss, A, Weller, RA, Khayrallah, M & Ascher, J 1996, 'Bupropion hydrochloride in attention deficit disorder with hyperactivity', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 35, no. 10, pp. 1314-1321. https://doi.org/10.1097/00004583-199610000-00018
Conners, C. Keith ; Casat, Charles D. ; Gualtieri, C. Thomas ; Weller, Elizabeth ; Reader, Mark ; Reiss, Allan ; Weller, Ronald A. ; Khayrallah, Moise ; Ascher, John. / Bupropion hydrochloride in attention deficit disorder with hyperactivity. In: Journal of the American Academy of Child and Adolescent Psychiatry. 1996 ; Vol. 35, No. 10. pp. 1314-1321.
@article{323ad2f16be54cd0a170fc33af7e746d,
title = "Bupropion hydrochloride in attention deficit disorder with hyperactivity",
abstract = "Objective: This is a multisite, double-blind, placebo-controlled trial to determine the safety and efficacy of bupropion in the treatment of children with attention deficit disorder with hyperactivity (ADDH). Method: In a four-center, double-blind comparison of bupropion (n = 72) and placebo (n = 37), children aged 6 to 12 years meeting DSM-III criteria for ADDH were randomized to receive bupropion 3 to 6 mg/kg per day or placebo, administered twice daily, at 7 A.M. and 7 P.M. Measures of efficacy included the Conners Parent and Teacher Questionnaires (93-item, 39-item, and 10-item), Clinical Global Impressions Scales of Severity and Improvement, the Sternberg Short- Term Memory Task, and the Continuous Performance Test Screen and posttreatment physical examinations, electrocardiograms, electroencephalograms, and clinical laboratory evaluations were performed. Height, weight, and vital signs were measured and adverse experiences were assessed weekly. Results: A significant treatment effect, apparent as early as day 3, was present for both conduct problems and hyperactivity on the Conners 10-item and 30-item teacher's checklist, and at day 28 for conduct problems and restless-impulsive behavior on the 93-item parent questionnaire. Findings were of smaller magnitude for parent ratings than teacher ratings. Significant treatment effects were present on both the Continuous Performance Test and memory retrieval test. Effect sizes of bupropion/placebo differences for teacher and parent ratings in this study were somewhat smaller than for standard stimulant drugs used to treat ADDH. Bupropion appeared to be well tolerated in most children. Dermatological reactions were twice as frequent in the drug group as the placebo group, with four reactions involving rash and urticaria that were serious enough to require discontinuation of medication. Conclusions: Bupropion may be a useful addition to available treatments for ADDH. Comparative trials with such standard drugs as methylphenidate are warranted to determine the relative clinical merits of bupropion.",
keywords = "attention deficit disorder with hyperactivity, attention- deficit hyperactivity disorder, bupropion",
author = "Conners, {C. Keith} and Casat, {Charles D.} and Gualtieri, {C. Thomas} and Elizabeth Weller and Mark Reader and Allan Reiss and Weller, {Ronald A.} and Moise Khayrallah and John Ascher",
year = "1996",
month = "1",
day = "1",
doi = "10.1097/00004583-199610000-00018",
language = "English (US)",
volume = "35",
pages = "1314--1321",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Bupropion hydrochloride in attention deficit disorder with hyperactivity

AU - Conners, C. Keith

AU - Casat, Charles D.

AU - Gualtieri, C. Thomas

AU - Weller, Elizabeth

AU - Reader, Mark

AU - Reiss, Allan

AU - Weller, Ronald A.

AU - Khayrallah, Moise

AU - Ascher, John

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Objective: This is a multisite, double-blind, placebo-controlled trial to determine the safety and efficacy of bupropion in the treatment of children with attention deficit disorder with hyperactivity (ADDH). Method: In a four-center, double-blind comparison of bupropion (n = 72) and placebo (n = 37), children aged 6 to 12 years meeting DSM-III criteria for ADDH were randomized to receive bupropion 3 to 6 mg/kg per day or placebo, administered twice daily, at 7 A.M. and 7 P.M. Measures of efficacy included the Conners Parent and Teacher Questionnaires (93-item, 39-item, and 10-item), Clinical Global Impressions Scales of Severity and Improvement, the Sternberg Short- Term Memory Task, and the Continuous Performance Test Screen and posttreatment physical examinations, electrocardiograms, electroencephalograms, and clinical laboratory evaluations were performed. Height, weight, and vital signs were measured and adverse experiences were assessed weekly. Results: A significant treatment effect, apparent as early as day 3, was present for both conduct problems and hyperactivity on the Conners 10-item and 30-item teacher's checklist, and at day 28 for conduct problems and restless-impulsive behavior on the 93-item parent questionnaire. Findings were of smaller magnitude for parent ratings than teacher ratings. Significant treatment effects were present on both the Continuous Performance Test and memory retrieval test. Effect sizes of bupropion/placebo differences for teacher and parent ratings in this study were somewhat smaller than for standard stimulant drugs used to treat ADDH. Bupropion appeared to be well tolerated in most children. Dermatological reactions were twice as frequent in the drug group as the placebo group, with four reactions involving rash and urticaria that were serious enough to require discontinuation of medication. Conclusions: Bupropion may be a useful addition to available treatments for ADDH. Comparative trials with such standard drugs as methylphenidate are warranted to determine the relative clinical merits of bupropion.

AB - Objective: This is a multisite, double-blind, placebo-controlled trial to determine the safety and efficacy of bupropion in the treatment of children with attention deficit disorder with hyperactivity (ADDH). Method: In a four-center, double-blind comparison of bupropion (n = 72) and placebo (n = 37), children aged 6 to 12 years meeting DSM-III criteria for ADDH were randomized to receive bupropion 3 to 6 mg/kg per day or placebo, administered twice daily, at 7 A.M. and 7 P.M. Measures of efficacy included the Conners Parent and Teacher Questionnaires (93-item, 39-item, and 10-item), Clinical Global Impressions Scales of Severity and Improvement, the Sternberg Short- Term Memory Task, and the Continuous Performance Test Screen and posttreatment physical examinations, electrocardiograms, electroencephalograms, and clinical laboratory evaluations were performed. Height, weight, and vital signs were measured and adverse experiences were assessed weekly. Results: A significant treatment effect, apparent as early as day 3, was present for both conduct problems and hyperactivity on the Conners 10-item and 30-item teacher's checklist, and at day 28 for conduct problems and restless-impulsive behavior on the 93-item parent questionnaire. Findings were of smaller magnitude for parent ratings than teacher ratings. Significant treatment effects were present on both the Continuous Performance Test and memory retrieval test. Effect sizes of bupropion/placebo differences for teacher and parent ratings in this study were somewhat smaller than for standard stimulant drugs used to treat ADDH. Bupropion appeared to be well tolerated in most children. Dermatological reactions were twice as frequent in the drug group as the placebo group, with four reactions involving rash and urticaria that were serious enough to require discontinuation of medication. Conclusions: Bupropion may be a useful addition to available treatments for ADDH. Comparative trials with such standard drugs as methylphenidate are warranted to determine the relative clinical merits of bupropion.

KW - attention deficit disorder with hyperactivity

KW - attention- deficit hyperactivity disorder

KW - bupropion

UR - http://www.scopus.com/inward/record.url?scp=0029819433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029819433&partnerID=8YFLogxK

U2 - 10.1097/00004583-199610000-00018

DO - 10.1097/00004583-199610000-00018

M3 - Article

C2 - 8885585

AN - SCOPUS:0029819433

VL - 35

SP - 1314

EP - 1321

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 10

ER -